{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:32:04Z","timestamp":1777051924588,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T00:00:00Z","timestamp":1395792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s10147-014-0687-1","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T01:18:39Z","timestamp":1395710319000},"page":"143-149","source":"Crossref","is-referenced-by-count":15,"title":["Clinical features of long-term survivors of recurrent epithelial ovarian cancer"],"prefix":"10.1007","volume":"20","author":[{"given":"Haruko","family":"Iwase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Iitsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihiko","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,26]]},"reference":[{"key":"687_CR1","volume-title":"Ovarian cancer treatment guidelines 2010","author":"Japan Society of Gynecologic Oncology","year":"2010","unstructured":"Japan Society of Gynecologic Oncology (2010) Ovarian cancer treatment guidelines 2010. Kanehara & Co., Ltd., Tokyo"},{"issue":"Suppl 1","key":"687_CR2","first-page":"S161","volume":"95","author":"APM Heinz","year":"2006","unstructured":"Heinz APM, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. FIGO sixth annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161\u2013S192","journal-title":"Int J Gynaecol Obstet"},{"key":"687_CR3","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A Bois du","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinscaht Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVER) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer 115:1234\u20131244","journal-title":"Cancer"},{"key":"687_CR4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","volume":"374","author":"BT Hennessy","year":"2009","unstructured":"Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374:1371\u20131382","journal-title":"Lancet"},{"key":"687_CR5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman M, Rothman R, Hakes T et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389\u2013393","journal-title":"J Clin Oncol"},{"key":"687_CR6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","volume":"36","author":"ME Gore","year":"1990","unstructured":"Gore ME, Fryatt I, Wiltshaw E et al (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207\u2013211","journal-title":"Gynecol Oncol"},{"key":"687_CR7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","volume":"59","author":"G Blackledge","year":"1989","unstructured":"Blackledge G, Lawton F, Redman C et al (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650\u2013653","journal-title":"Br J Cancer"},{"key":"687_CR8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(02)00847-1","volume":"3","author":"M Harries","year":"2002","unstructured":"Harries M, Gore M (2002) Part II: chemotherapy for epithelial ovarian cancer\u2013treatment of recurrent disease. Lancet Oncol 3:537\u2013545","journal-title":"Lancet Oncol"},{"key":"687_CR9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ygyno.2006.10.020","volume":"104","author":"A Santillan","year":"2007","unstructured":"Santillan A, Karam AK, Li AJ et al (2007) Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 104:686\u2013690","journal-title":"Gynecol Oncol"},{"key":"687_CR10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2009.11.008","volume":"116","author":"A Gadducci","year":"2010","unstructured":"Gadducci A, Cosio S, Zola P et al (2010) The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study. Gynecol Oncol 116:358\u2013363","journal-title":"Gynecol Oncol"},{"key":"687_CR11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.22447","volume":"109","author":"R Salani","year":"2007","unstructured":"Salani R, Santillan A, Zahurak ML et al (2007) Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer. Analysis of prognostic factors and survival outcome. Cancer 109:685\u2013691","journal-title":"Cancer"},{"key":"687_CR12","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/sj.bjc.6602466","volume":"92","author":"T Onda","year":"2005","unstructured":"Onda T, Yoshikawa H, Yasugi T et al (2005) Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 92:1026\u20131032","journal-title":"Br J Cancer"},{"key":"687_CR13","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","volume":"106","author":"DS Chi","year":"2006","unstructured":"Chi DS, McCaughty K, Diaz JP et al (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933\u20131939","journal-title":"Cancer"},{"key":"687_CR14","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/1097-0142(19951101)76:9<1606::AID-CNCR2820760917>3.0.CO;2-H","volume":"76","author":"SM Eisenkop","year":"1995","unstructured":"Eisenkop SM, Fridedman RL, Wang HJ (1995) Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 76:1606\u20131614","journal-title":"Cancer"},{"key":"687_CR15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/1096-9098(200009)75:1<24::AID-JSO5>3.0.CO;2-L","volume":"75","author":"RY Zang","year":"2000","unstructured":"Zang RY, Zhang ZY, Li ZT et al (2000) Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 75:24\u201330","journal-title":"J Surg Oncol"},{"key":"687_CR16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","volume":"88","author":"SM Eisenkop","year":"2000","unstructured":"Eisenkop SM, Fridedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian cancer. Cancer 88:144\u2013153","journal-title":"Cancer"},{"key":"687_CR17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.10789","volume":"95","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Gossett DR, Shook DR et al (2002) Recurrent micropapillary serous ovarian carcinoma. Cancer 95:791\u2013800","journal-title":"Cancer"},{"key":"687_CR18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","volume":"107","author":"U Wagner","year":"2012","unstructured":"Wagner U, Marth C, Largiller R et al (2012) Final survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107:588\u2013591","journal-title":"Br J Cancer"},{"key":"687_CR19","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff A et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039\u20132045","journal-title":"J Clin Oncol"},{"key":"687_CR20","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orland M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811\u20132818","journal-title":"J Clin Oncol"},{"key":"687_CR21","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.ejca.2009.05.016","volume":"45","author":"I Vergote","year":"2009","unstructured":"Vergote I, Finkler N, del Campo J et al (2009) Phase 3 randomized study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 45:2324\u20132332","journal-title":"Eur J Cancer"},{"key":"687_CR22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/IGC.0b013e31823eed2c","volume":"22","author":"H Kajiyama","year":"2012","unstructured":"Kajiyama H, Shibata K, Mizuno M et al (2012) Long-term clinical outcome of patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 22:394\u2013399","journal-title":"Int J Gynecol Cancer"},{"key":"687_CR23","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699\u20134707","journal-title":"J Clin Oncol"},{"key":"687_CR24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/annonc\/mdl376","volume":"18","author":"JM Ferrero","year":"2007","unstructured":"Ferrero JM, Weber B, Geay JF et al (2007) Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18:263\u2013268","journal-title":"Ann Oncol"},{"key":"687_CR25","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gyn\u00e4ekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702\u20131710","journal-title":"Ann Surg Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-014-0687-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-014-0687-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-014-0687-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T17:45:31Z","timestamp":1565286331000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-014-0687-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,26]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s10147-014-0687-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,26]]}}}